Corneal ulcer

Retinol (Vitamin A) Global Market Report 2022: Excellent Pharmacodynamic and Pharmacokinetic Effects Propels Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 30, 2022

The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinol (Vitamin A) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030" report has been added to ResearchAndMarkets.com's offering.
  • Natural retinol is obtained from sources such as sweet potatoes, carrots, apricots, oranges, eggs, meat and dairy products.
  • They are present in very small quantities in daily dietary intake which led to the demand for synthetic retinol.
  • The factors responsible for their increasing demand are excellent pharmacodynamic and pharmacokinetic properties possessed by synthetic retinol.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Wednesday, September 28, 2022

The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.

Key Points: 
  • The AAO Annual Meeting is among the largest gatherings of ophthalmic physicians, medical personnel, and industry executives in the ophthalmic industry.
  • All educational content of the AAO Annual Meeting is planned by its program committee, and AAO does not endorse, promote, approve or recommend the use of any products, devices or services.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.

Can you sleep with contact lenses in?

Retrieved on: 
Tuesday, July 19, 2022

LAS VEGAS, July 19, 2022 /PRNewswire/ -- Contact lenses are wonderful because they provide a near-normal vision experience without corrective glasses. But they can be easily forgotten. When preparing to sleep, even for a nap, is not the time to forget about them.

Key Points: 
  • When you sleep in your contact lenses, your risk of contracting eye infections increases six to eight times.
  • Another reason is that contact lenses designed for overnight wear are made of thinner material compared to daily wear contact lenses.
  • While modern soft contact lenses have incredible technology to ensure enough oxygen passes through the lenses in daily wear, having your eyes closed while you sleep reduces available oxygen and prevents tears from washing your eye under the contact lenses.
  • Founded in 1995, Lens.com, Inc. is the nation's 2ndlargest online retailer for contact lenses , offering consumers all the popular brands of contact lenses at wholesale prices with convenient quick delivery.

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Retrieved on: 
Thursday, May 26, 2022

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced additional efficacy data from the pivotal SORAYA study evaluating mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FR)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab) and an integrated safety summary of single-agent mirvetuximab across multiple studies in patients with FR-positive recurrent ovarian cancer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced additional efficacy data from the pivotal SORAYA study evaluating mirvetuximab soravtansine (mirvetuximab) monotherapy in patients with folate receptor alpha (FR)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab) and an integrated safety summary of single-agent mirvetuximab across multiple studies in patients with FR-positive recurrent ovarian cancer.
  • SORAYA enrolled 106 platinum-resistant ovarian cancer patients with high FR expression who have been previously treated with 1 to 3 prior systemic treatments, at least one of which included bevacizumab.
  • If approved, I look forward to being able to offer mirvetuximab to my patients and continuing to support its further development in patients with ovarian cancer."
  • ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.

Johnson & Johnson Vision Named a Winner of Fast Company's 2022 World Changing Ideas Awards for ACUVUE® Theravision™ with Ketotifen

Retrieved on: 
Wednesday, May 4, 2022

JACKSONVILLE, Fla., May 4, 2022 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson MedTech Companies†, was recognized as the winner of Fast Company's 2022 World Changing Ideas Awards in the Wellness category for ACUVUE® Theravision™ with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen). Each lens contains 19 mcg ketotifen. Fast Company also selected ACUVUE® Theravision™ with Ketotifen for an honorable mention in both the Health and Enduring Impact: 15+ Years in Business categories.

Key Points: 
  • At Johnson & Johnson Vision, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health around the world.
  • *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
  • The Johnson & Johnson MedTech Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson's MedTech segment.
  • Peter Menziuso is an employee of Johnson & Johnson Vision, Inc. with oversight as the Company Group Chairman of the Vision Care organization.

The Worldwide Corneal Transplantation Industry is Expected to Reach $640 Million by 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022

The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.

Key Points: 
  • The corneal transplantation market is projected to reach $640.79 million by 2028 from $420.71 million in 2021; it is estimated to grow at a CAGR of 6.2% during 2021-2028.
  • However, the risks associated with Corneal Transplantation and shortage of donor material hampers the market growth.
  • Corneal blindness has complex epidemiology that includes a broad spectrum of infectious and inflammatory eye diseases causing corneal scars that contribute to functional blindness.
  • Trachoma, corneal ulcers, ophthalmia neonatorum, xerophthalmia, viral infections, onchocerciasis, leprosy, traditional eye medications, and eye injuries lead to corneal blindness.

Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen - World's First and Only Drug-Eluting Contact Lens

Retrieved on: 
Wednesday, March 2, 2022

Problems with contact lenses or lens care products could result in serious injury to the eye.

Key Points: 
  • Problems with contact lenses or lens care products could result in serious injury to the eye.
  • *Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
  • The Johnson & Johnson Medical Device Companies comprise the surgery, orthopedics, vision, and interventional solutions businesses within Johnson & Johnson's Medical Devices segment.
  • Thomas Swinnen is an employee of Johnson & Johnson Vision Care, Inc.
    1Pall, B., Gomes, P., Yi, F., & Torkildsen, G. (2019).

Trefoil Therapeutics Announces Third Tranche of $28 Million Series A Financing Based on Achievement of Clinical Trial Objectives

Retrieved on: 
Wednesday, December 1, 2021

This funding allows Trefoil to expand the STORM clinical program and initiate a clinical trial of the topical formulation.

Key Points: 
  • This funding allows Trefoil to expand the STORM clinical program and initiate a clinical trial of the topical formulation.
  • Christy Shaffer, PhD, General Partner of Hatteras Venture Partners and Trefoil board member commented: Trefoil has exceeded our expectations.
  • With the clinical data the company has generated, Trefoil has the potential to transform how diseases like Fuchs dystrophy are treated.
  • Future clinical trial results may not demonstrate safety and efficacy sufficient to obtain regulatory approval related to the nonclinical research findings discussed in this press release.

Alley Cat Allies Files Legal Action in Supreme Court of Appeals of West Virginia Against Berkeley County Animal Control for Violations of Animal Cruelty Laws

Retrieved on: 
Thursday, November 25, 2021

Animal cruelty laws of West Virginia make it a crime "for any person to intentionally, knowingly or recklessly .

Key Points: 
  • Animal cruelty laws of West Virginia make it a crime "for any person to intentionally, knowingly or recklessly .
  • "West Virginia's animal cruelty laws apply just as much to Berkeley County Animal Control as to any member of the general public, especially since it is the very public office created to uphold these laws," said Becky Robinson, president and founder of Alley Cat Allies.
  • The Alley Cat Allies investigation revealed further neglect by Berkeley County Animal Control involving a dog named Kimberly.
  • This dog was euthanized by Berkeley County Animal Control after suffering 15 or 16 days in its care.

Alley Cat Allies Files Legal Action in Supreme Court of Appeals of West Virginia Against Berkeley County Animal Control for Violations of Animal Cruelty Laws

Retrieved on: 
Wednesday, November 24, 2021

Animal cruelty laws of West Virginia make it a crime "for any person to intentionally, knowingly or recklessly .

Key Points: 
  • Animal cruelty laws of West Virginia make it a crime "for any person to intentionally, knowingly or recklessly .
  • "West Virginia's animal cruelty laws apply just as much to Berkeley County Animal Control as to any member of the general public, especially since it is the very public office created to uphold these laws," said Becky Robinson, president and founder of Alley Cat Allies.
  • "Justice for the animals abused in Berkeley County Animal Control is our top priority.
  • The Alley Cat Allies investigation revealed further neglect by Berkeley County Animal Control involving a dog named Kimberly.